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Abstract Dramatic changes in glycan biosynthesis during on-
cogenic transformation result in the emergence of marker gly-
cans on the cell surface. We analysed the N-linked glycans of
L1CAM from different stages of melanoma progression, using
high-performance liquid chromatography combined with exo-
glycosidase sequencing, matrix-assisted laser desorption/ionisa-
tion time-of-flight mass spectrometry, and lectin probes.
L1CAM oligosaccharides are heavily sialylated, mainly diga-
lactosylated, biantennary complex-type structureswith galactose
β1-4/3-linked to GlcNAc and with or without fucose α1-3/6-
linked to GlcNAc. Hybrid, bisected hybrid, bisected trianten-
nary and tetraantennary complex oligosaccharides, and β1-6-
branched complex-type glycans with or without lactosamine
extensions are expresses at lower abundance. We found that
metastatic L1CAM possesses only α2-6-linked sialic acid and
the loss of α2-3-linked sialic acid in L1CAM is a phenomenon
observed during the transition of melanoma cells fromVGP to a
metastatic stage. Unexpectedly, we found a novel monoanten-
nary complex-type oligosaccharide with a Galβ1-4Galβ1- epi-
tope capped with sialic acid residues A1[3]G(4)2S2-3. To our
knowledge this is the first report documenting the presence of
this oligosaccharide in human cancer. The novel and unique
N-glycan should be recognised as a new class of human mela-
noma marker. In functional tests we demonstrated that the
presence of cell surface α2-3-linked sialic acid facilitates the
migratory behaviour and increases the invasiveness of primary
melanoma cells, and it enhances the motility of metastatic cells.
The presence of cell surfaceα2-6-linked sialic acid enhances the
invasive potential of both primary and metastatic melanoma
cells. Complex-type oligosaccharides in L1CAM enhance the
invasiveness of metastatic melanoma cells.
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ESI-FT-ICR Electrospray ionization Fourier
transform ion cyclotron resonance
FBS Fetal bovine serum
Hex Hexose
HexNAc N-Acetylhexosamine
LacNAc type 1 Galβ1-3GlcNAcβ-
LacNAc type 2 Galβ1-4GlcNAcβ-
Lea Galβ1-3(Fucα1-4)GlcNAcβ-
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NGS Normal goat serum
NP HPLC Normal phase high-performance
liquid chromatography
RGP Radial growth phase
TOF Time-of-flight
VGP Vertical growth phase
Introduction
Alterations of the cell surface carbohydrate structures of can-
cer cells are suggested to affect normal cellular interactions
and have been shown to facilitate tumour cell colonisation and
metastasis. The cancer-associated changes include underex-
pression and overexpression of naturally occurring glycans,
the appearance of incomplete or truncated structures, the
appearance of novel structures, and neoexpression of glycans
normally restricted to embryonic tissues [1–3]. One such
frequently observed membrane modification is altered expres-
sion of β1-6-branched N-linked glycans, caused by increased
transcription and activity of β1,6-N-acetylglucosaminyltrans-
ferase V (GnT-V). The β1-6-branched N-linked oligosacchar-
ides are believed to aid metastasis by making the cells more
invasive, although the mechanism is not very clear [4, 5].
Most of the cell lines expressing these oligosaccharides have
been shown to metastasize to either the liver or the lungs [6,
7]. β1-6 branching facilitates the synthesis of poly-N-acetyl-
lactosamine repeats and Lewis structures, as well as terminal
capping by sialic acid [1]. The N-acetyllactosamine unit and
poly-N-acetyllactosamine repeats should serve as high-
affinity ligands for galectins, which are expressed in various
cells and tissues including the lung endothelium [1, 8]. The
sialylated Lewis antigens on these oligosaccharides are in-
volved in selectin-mediated adhesion of cancer cells to the
vascular endothelium, and these determinants are thought to
be closely associated with hematogenous metastasis of cancer
[2]. A positive correlation has been demonstrated between the
metastatic ability of various cell lines and increased cell sur-
face sialylation and/or differences in the position of sialic
residues [1, 9]. To understand the role of these oligosacchar-
ides in tumour progression it is important to determine the
terminal substitutions and identify the glycoproteins that carry
them. In malignant transformation the abnormal oligosacchar-
ides are widely expressed on cell adhesion molecules (CAMs)
such as β1 and β3 integrin subunits, a few of the α integrin
subunits, CD44, and cadherins [10–15]. Another one of these
membrane-bound CAMs, known to be a valuable marker for
poor prognosis in several types of cancer, is the L1cell adhe-
sion molecule.
The L1cell adhesion molecule (L1CAM, CD171), a
member of the immunoglobulin (Ig) superfamily, is a 200–
220 kDa transmembrane glycoprotein. The ectodomain,
consisting of six immunoglobulin-like domains and five
fibronectin-like repeats (type III), is linked via a single
transmembrane sequence to a phylogenetically conserved
cytoplasmic domain. L1CAM possesses 21 potential N-
glycosylation sites located on Ig domains and FNIII domains
of the ectodomain (http://www.ncbi.nlm.nih.gov/PROW/
guide/1813332452_g.htm), but the pattern of glycosylation
is still unknown. L1CAM was initially identified in neural
cells, but its expression has also been seen in some other
normal tissues and in several types of human carcinomas
and melanomas [16–20]. L1CAM expression in carcinomas
increases the dissemination of tumour cells by enabling cell
migration and invasion [16, 18] and promotes the epithelial–
mesenchymal transition [19]. In melanoma the expression of
L1CAM occurs in a stage-dependent manner; L1CAM is
expressed in primary melanomas and cutaneous metastases
and not in melanocytic nevi and melanocytes [18].
The mechanism by which the L1 cell adhesion molecule
contributes to tumour progression has not been clearly
established. In this work we used HPLC and mass spec-
trometry techniques to determine the N-glycan profile of the
L1 cell adhesion molecule from primary vertical growth
phase (VGP) and metastatic melanoma cells. Unexpectedly,
we found an unknownmonoantennary complex-type structure
with a novel oligosaccharide branch on the C3-linked an-
tenna. Using lectins, molecules which recognise and
bind specific mono- and oligosaccharides, we confirmed
the findings from structural studies. In functional tests
we showed the importance of L1CAM glycans in the
migratory and invasive behaviour of melanoma cells.
Materials and methods
Materials
Unsubstituted and substituted lectins, FITC-Avidin as well
as Vectashield Hardset™ mounting medium with DAPI
were purchased from Vector (USA). Anti-mouse IgG/AP,
and DIG Glycan Differentiation Kit were purchased from
Boehringer (Mannheim, Germany). Immunoprecipitation
Kit (Protein G), N-glycosidase F (PNGase F), and neuramin-
idase from Arthrobacter ureafaciens were purchased from
Roche (Mannheim, Germany). Sialidase A, β-galactosidase
(Streptococcus pneumoniae), β-N-acetylhexosaminidase
(Jack Bean), α-fucosidase (Bovine Kidney), α-mannosidase
(Jack Bean), Signal 2-AB Labelling Kit as well as GlycoSep
N column were from Prozyme (San Leandro, CA).
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Immobilon-P transfer membrane, Micropure-EZ column and
rabbit anti-mouse IgG/AP were obtained from Millipore and
Chemicon (USA), respectively. Mouse anti-human L1CAM
mAbs, clone UJ127.11, α2-3-neuraminidase from
Streptococcus pneumonia, RPMI 1640 with GlutaMax-I me-
dium (Gibco, UK), Protein Assay Kit, ExtrAvidin/AP, normal
goat serum, protease inhibitor cocktail, swainsonine,
GlycoProfile 2-AB Labelling Kit and GlycoProfile Glycan
Clean-up columns were obtained from Sigma (St. Louis,
MO). Alexa Fluor Cy3-conjugated goat anti-mouse mAbs,
and foetal bovine serum were from Invitrogen (USA).
Carbograph SPE Extract-Clean columns were obtained from
Alltech (Deerfield, IL). BD Falcon FluoroBlok™ 96-
Multiwell Insert System, 96-well BD BioCoat™ Tumor
Invasion System and DiIC12(3) fluorescent dye were from
BD Biosciences. All other chemicals were of the highest
purity and were purchased from Sigma (St. Louis, MO).
Cell lines
Human cutaneous primary melanoma cell lines: WM793
(VGP), FM-55-P, IGR-39, WM1552C (RGP), WM75
(VGP) and metastatic melanoma cell lines: WM1205Lu (lung
metastasis), M6/B7 and UKRV-Mel-15a were obtained from
the ESTDAB Melanoma Cell Bank (Tübingen). Metastatic
melanoma cell line Ma-Mel-27 was kindly donated by Prof.
D. Schadendorf of the Klinik für Dermatologie, Venerologie
und Allergologie (Universitätsklinikum Essen, Germany).
Cell culture conditions and cell extract preparation
Cells were maintained in RPMI 1640 medium with
GlutaMax-I supplemented with 10 % foetal bovine serum,
100 units/ml penicillin and 100 μg/ml streptomycin. Cells
were grown in monolayers in a 5 % CO2 atmosphere at
37 °C in a humidified incubator. Cell extract proteins were
prepared on ice by sonication (Bandelin Electronic) of cells in
50 mM Tris/HCl buffer (pH 7.5) containing 1 mM EDTA,
protease inhibitor cocktail (20 μl/ml) and 1 mM PMSF. Triton
X-100 (final concentration 1 %) and protamine sulfate (final
concentration 0.3 %) were added and the homogenates were
incubated for 30 min. Cell extracts were cleared by centrifu-
gation at 18,000×g for 20 min at 4 °C. The protein concen-
tration was determined with the Protein Assay Kit. All cell
cultures were free of Mycoplasma infection as verified by
PCR and by DAPI staining under confocal microscopy.
Isolation of L1CAM from cell extract
L1CAM was immunoprecipitated with a Protein G
Immunoprecipitation Kit according to the manufacturer’s
protocol. Briefly, cleared cell extracts of WM793 and
WM1205Lu cell lines (10 mg total protein) were incubated
with 50 μg UJ127.11 mAb for 18 h at 4 °C. Subsequently,
40 μl Protein G-agarose was added to each immunoprecip-
itate and incubated for another 4 h at 4 °C. Samples were
boiled in 100 μl Laemmli sample buffer containing 5 % β-
mercaptoethanol at 100 °C for 8 min. Both immunoprecipi-
tates were electrophoresed in a 7.2 % SDS-polyacrylamide
gel according to Laemmli [21] until the standard-mass pro-
tein of 116 kDa went out of the gel. After electrotransfer on
a PVDF membrane, immunodetection of L1CAM was per-
formed using mAbs UJ127.11 (1:12500 dilution) and rabbit
anti-mouse IgG/AP (1:4000 dilution) as secondary antibody.
The conjugated alkaline phosphatase was detected by NBT/
X-phosphate staining.
Release and purification of N-linked oligosaccharides
N-glycans were released from purified L1CAM by in situ
digestion with PNGase F according to [22] with minor mod-
ifications. Briefly, individual protein bands corresponding to
L1CAM were excised from the PVDF membrane, reduced,
alkylated and treated with PNGase F to release N-linked
glycans. Glycans were purified on Carbograph SPE Extract-
Clean columns according to the manufacturer’s protocol and
then dried in vacuo.
Fluorescent labelling of the reducing terminus
of oligosaccharides
Oligosaccharides were fluorescence-labelled with 2-AB by
reductive amination using the GlycoProfile 2-AB Labelling
Kit. Labelled oligosaccharides were purified on GlycoProfile
Glycan Clean-up columns according to the manufacturer’s
protocol and then dried in vacuo.
Simultaneous oligosaccharide sequencing
by exoglycosidase digestions
The 2-AB labelled oligosaccharides were split into six equal
parts, five of which were incubated overnight at 37 °C in
parallel with 3 μl of each of the following exoglycosidase
arrays prepared in 20 mM sodium acetate buffer, pH 5.5: (i)
Arthrobacter ureafaciens sialidase (α2-3,6,8 sialic acid, 2
U/ml); (ii) sialidase and Streptococcus pneumoniae β-
galactosidase (β1-4 galactose, 80 mU/ml); (iii) sialidase,
galactosidase, and bovine kidney α-fucosidase (α1-2,6,3,4
fucose, 1 U/ml); (iv) sialidase, galactosidase, fucosidase,
and Jack bean β-N-acetylhexosaminidase (GlcNAc β1-
2,3,4,6 > bisect, 30 U/ml); and (v) sialidase, galactosidase,
fucosidase, N-acetylhexosaminidase, and Jack bean α-
mannosidase (α1-2,6,3 mannose, 100 U/ml). Each reaction
mixture was desalted and freed of enzymes by using
Micropure-EZ column, according to manufacturer’s proto-
col. All samples were dried in vacuo.
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Normal-phase HPLC
2-AB-labelled sugars were separated on a 4.6×250 mm
Glyco-Sep N column using two Shimadzu LC-10ADvp
pumps and a Shimadzu RF-10Ax1 fluorescence detector
(Japan). The gradient used was as described by [23]: solvent
A, acetonitrile; solvent B, 50 mM ammonium formate, pH
4.4. Initial conditions were 20%B at a flow rate of 0.4 ml/min
followed by a linear gradient of 20–53 % B over 132 min
followed by 53–100 % B over the next 3 min. The column
was washed with 100 % B for 5 min at a flow rate of 1 ml/min
before reequilibration in the initial solvent system.
MALDI-TOF mass spectrometry
Positive Reflectron MALDI spectra were recorded on a
Voyager DE STR instrument (Applied Biosystems,
Framingham, MA). The MALDI matrix was prepared by
dissolving 10 mg of 2,5-dihydroxybenzoic acid (2,5-DHB
in acetonitrile/water (9:1 v/v). Typically, 1 μl of matrix was
applied to the metallic sample plate and 1 μl of analyte was
then added. Acceleration and reflector voltages were set up
as follows: target voltage at 20 kV, first grid at 65 % of
target voltage, delayed extraction at 400 ns to obtain the best
signal-to-noise ratios and the best possible isotopic resolu-
tion with multipoint external calibration using calibrant
mixture purchased from Applied Biosystems. Each spec-
trum represents the sum of 3,000 laser pulses from randomly
chosen spots per sample position. Raw data were analysed
using the computer software provided by the manufacturers
and are reported as monoisotopic masses.
Lectin precipitation and western blotting
The cleared cell extracts (250 μg total protein per sample)
were diluted 1:1 (v/v) with incubation buffer containing
10 mM HEPES, 150 mM NaCl, 0.1 mM CaCl2 and
0.01 mM MgCl2, pH 7.5, and incubated overnight at 4 °C
with 8 μl biotinylated lectins or with 40 μl agarose-bound
lectins. Then the samples with biotinylated lectins were
mixed with 40 μl streptavidin-agarose for another 4 h at
4 °C. All precipitates were washed three times with incuba-
tion buffer and once with PBS, with centrifugation each
time (1,500×g, 3 min). Precipitated glycoproteins were
liberated by boiling in Laemmli sample buffer containing
5 % β-mercaptoethanol and 1 mM EDTA at 100 °C for
8 min. Electrophoresis and western blotting were performed
as described above.
Immunoprecipitation and lectin blotting
Cell extracts of WM793 and WM1205Lu cell lines (1.8 mg
total protein each) were immunoprecipitated with 8 μg mAb
UJ127.11 for 18 h at 4 °C. Next, 20 μl Protein G-agarose
(Immunoprecipitation Kit) was added to each of the immu-
noprecipitates and incubated for another 4 h at 4 °C. The
immunoprecipitates of the WM793 and WM1205Lu cell
lines were divided into six equal parts for lectin probes (each
part equivalent to 300 μg total protein). Electrophoresis,
electrotransfer and immunodetection of L1CAM on PVDF
membranes were performed as above. For on blot lectin
probing we used the following digoxigenin-labelled GNA
(1:2000 dilution; DIG Glycan Differentiation Kit) and
biotin-labelled lectins (1:4000 dilution): MAA, SNA,
LEA, PHA-E, PHA-L, DSA, AAA and UEA-I. After wash-
ing, the respective membranes were incubated with anti-
digoxigenin-AP and ExtrAvidin-AP conjugate (1:4000 dilu-
tion) for 1 h at RT. Conjugated alkaline phosphatase was
detected by NBT/X-phosphate staining.
Double immunofluorescence
Cells were plated on glass slides and grown in four-well
plates (Nunc, Germany) to reach 80 % confluence. Cells
were fixed with 2 % PFA for 10 min at RT. After blocking
with 10 % NGS and 2 % BSA/PBS for 30 min at RT the
cells were incubated with biotinylated or FITC-conjugated
lectin (dilution 1:500) in 1 % BSA/PBS for 2 h at RT. When
biotinylated lectins were used an additional incubation was
done with ExtraAvidin-AlexaFluor488 (dilution 1:100) in
1 % BSA/PBS for 2 h at RT. Then an incubation was
performed with mAb UJ127.11 (diluted 1:100) in 1 %
BSA/PBS overnight at RT, and then with Cy3-conjugated
goat anti-mouse IgG (diluted 1:300) in 1 % BSA/PBS for
2 h at RT. Cells were mounted in Vectashield Hardset™
mounting medium with DAPI and observed under a confo-
cal microscope (Zeiss LSM 510 META, Carl Zeiss
MicroImaging GmbH, Jena, Germany).
Wound healing assay
Scrape-wound healing assays were performed in a 6-well
culture plate as described in detail by [11]. Briefly, WM793
and WM1205Lu cells were grown to confluence. After
aspiration of the medium, the cell-coated surface was
scraped with a 200 μl pipette tip in a single stripe. Then
the surface was washed twice with RPMI 1640 and covered
with medium supplemented with 10 % FBS. A photograph
of each wound was taken through an inverted microscope
with a digital camera (Canon Powershot G10). The wounds
were allowed to heal for 22 h at 37 °C and then photo-
graphed. In some experiments the wound healing assay was
performed in the presence of one of the following reagents:
anti-L1CAM (UJ127.11; 10 μg/ml), swainsonine (SW;
10 μl/ml), MAA (50 μg/ml) or SNA (50 μg/ml). In other
experiments we used one of the following reagent
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combinations: anti-L1CAM and SW, anti-L1CAM and
MAA, or anti-L1CAM and SNA. The average extent of
wound closure was quantified from twenty measurements
of the width of the wound space in two separate trials for
each of these treatments, using AxioVision software (Carl
Zeiss). Values are expressed as the means ± standard devi-
ation of three separate experiments. Changes in cell migra-
tion rate after antibody, lectin and SW treatments were
calculated by comparing the migration of untreated (taken
as 100 % migration) and treated cells.
Matrigel invasion assay
Cells were grown in the presence or absence of SW
(10 μg/ml) for 24 h at 37 °C in a 5 % CO2 atmosphere and
then labelled with DiIC12(3) fluorescent dye. Invasion assays
were performed using DiIC12(3) pre-labelled cells (12.5×103
cells/well) suspended in serum-free RPMI 1640 and plated
onto either uncoated (BD Falcon FluoroBlok™ 96-Multiwell
Insert System) or matrigel-coated filters (96-well BD
BioCoat™ Tumor Invasion System). As chemoattractant,
5 % FBS in RPMI 1640 medium was placed in the lower
chambers. In the experimental treatments, tumour cells grown
in the absence of SW before the invasion assays were plated in
wells in the presence or absence of anti-L1CAM antibody
(40 μg/ml; UJ127.11). Tumour cells grown in the presence
of SW before invasion assays were plated in wells in the
presence of SW (10 μg/ml) or in the presence of both the
antibody (40 μg/ml; UJ127.11) and SW (10 μg/ml). In some
experiments, after labelling with fluorescent dye and before
invasion assays, tumour cells were desialylated with neurami-
nidases from Arthrobacter ureafaciens or Streptococcus pneu-
moniae for 1 h at 37 °C and then incubated in serum-free
medium in the absence or presence of antibody (40 μg/ml;
UJ127.11) for another 1 h at 37 °C. Finally, the tumour cells
were seeded in the wells. After 17 h incubation at 37 °C in a
5 % CO2 atmosphere, the fluorescence of cells in the lower
chambers was measuredwith a BioTek Synergy™ instrument.
Each experiment was done two or three times, with four
repetitions for each sample, and the mean values ± standard
deviation were calculated.
Results
The main aim of this study was to determine the N-
glycosylation pattern of the L1CAM molecule at different
stages of melanoma progression and to evaluate the effect of
these glycans on melanoma cell behaviour. We used isogenic
human melanoma cell lines: the weakly tumourigenic mela-
noma parentalWM793 cell line, and its metastatic counterpart
WM1205Lu from a spontaneous lung metastasis after subcu-
taneous injection of parental cells to mice. This approach
eliminated the diversity of genetic backgrounds between indi-
viduals and eliminated variability due to sex, age, previous
history, etc. Supplementary Figure S1 represents our research
design. The advantage of our protocol is that it combined high
performance liquid chromatography with sequential exogly-
cosidase digestion, revealing structural details such as anom-
ericity and linkage positions, complemented by matrix-
assisted laser desorption/ionisation time-of-flight (MALDI-
TOF) mass spectrometry. We analysed the N-glycosylation
pattern of L1CAM protein, corresponding to a molecular
weight of 220 kDa. The whole pool of 2AB-labelled oligo-
saccharides was divided into six equal parts, five of which
were subjected to exoglycosidase digestion arrays. Each
pool was separately fractionated on a GlycoSep N col-
umn and analysed on the basis of the shift in the
elution profile after treatment with the given exoglyco-
sidase mixture and on the basis of changes in the
relative areas of peaks, using the on-line GlycoBase 2
database. The elution position of each peak was de-
scribed in glucose units (GU) by comparison with the
elution positions of a standard 2AB-labelled dextran
hydrolysate mixture [23]. In parallel, other portions of
PNGase F-released and desialylated N-glycan pools
were subjected to MALDI-TOF MS. Glycans were ana-
lysed on the basis of their pseudomolecular ion masses.
The presence of the glycan structures found was con-
firmed after immunoprecipitation by on blot probing
with a set of lectins, by lectin precipitation with subse-
quent western blotting, and by lectin staining in confo-
cal microscopy. A scrape-wound assay and a matrigel
invasion assay were done for the functional studies.
Normal phase HPLC of L1CAM oligosaccharides
from WM793 primary melanoma cells
The 2AB-labelled untreated glycan pool was resolved on a
GlycoSepN column into fourteen peaks with GU values
from 4.39 to 11.22 (Fig. 1a). Treatment with Arthrobacter
ureafaciens sialidase (ABS; specificity for α2-3,6,8-linked
terminal NeuAc and NeuGc; Fig. 1b) resulted in the forma-
tion of a dominating broad peak with a GU value of 7.05
(peak 7) and at least sixteen other peaks. Upon digestion
with a mixture of ABS and Streptococcus pneumoniae ga-
lactosidase (SPG; specificity for β1-4-linked galactose;
Fig. 1c), the dominating broad peak 7 produced four higher
peaks with GU values of 5.05, 5.47, 6.27 and 7.09. The peak
with a GU value of 5.05 was not expected, because it had
arisen from the peak with a GU value of 7.05 by losing 2.00
GU corresponding to two galactose residues on the C3-
linked antenna [24]. This peak did not change its position
after further treatment with a mixture of ABS, SPG and
bovine kidney fucosidase (BKF; specificity for α1-2 or
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Fig. 1 HPLC profiles of the
N-glycan pool of L1CAM from
primary WM793 cell line
simultaneously digested with a
series of enzyme arrays. HPLC
analysis of the total glycan pool
a and the products resulting
from digestion of five aliquots
of the total glycan pool with a
series of enzyme arrays b–f.
The enzymes used were as
follows: ABS, Arthrobacter
ureafaciens sialidase (removes






cose); JBH, jack bean α-N-
acetylhexosaminidase (removes
GlcNAc); JBM, jack bean α-
mannosidase (removes α1-
2,6,3-linked mannose). The
glucose unit (GU) value of each
peak was calculated by com-
parison with the dextran hydro-
lysate ladder shown at the
bottom of the figure. Structures
were assigned from the glucose
unit values, the known incre-
mental values for monosaccha-
ride residues and the known
specificity of the exoglycosi-
dase enzymes. The structure
abbreviations used were as fol-
lows: all N-glycans have two
core GlcNAcs, Aa[3/6] indi-
cates the number “a” of anten-
nae on the trimannosyl core
linked to the 3/6-mannose arm;
G(4)b and Gc indicate the
number “b” and “c” of terminal
galactose residues β1-4- and
β1-3-linked to antenna GlcNAc
respectively; F(6) and F(3)d in-
dicate a core fucose α1-6-
linked to the core GlcNAc and
“d” fucose residues α1-3-linked
to antenna GlcNAc respective-
ly; B, represents bisecting
GlcNAc β1-4-linked to core
mannose; Me represents the
number “e” of mannose resi-
dues; Sf represents the number
“f” of sialic acids linked to the
galactose or N-acetylglucos-
amine in antennae. Dotted lines
indicate the shifts of the glycans
digested by the subsequent en-
zyme array. M1 structure with a
GU value of 2.70 is outside the
chromatogram (panel f)
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α1-6-linked fucose; Fig. 1d). Addition of Jack bean β-N-
acetylhexosaminidase (JBH; specificity for β1-2,3,4,6-
linked GlcNAc and GalNAc; Fig. 2e) resulted in the forma-
tion of M3 structure (GU 4.39) from this peak. We conclud-
ed that peak 7 (Fig. 1b) possessed A1 structure with a novel
oligosaccharide branch on the C3-linked antenna (see leg-
end to Fig. 1 for nomenclature) and we suggest as most
probable a monoantennary complex-type structure: A1[3]G
(4)2. The proposed structure was supported by the enzymat-
ic specificity of SPG, which at a concentration below
100 mU/ml removes only galactose β1-4-linked to
GlcNAc. Moreover, judging from this GU value and the
presence of a neighbouring peak with a GU value of 4.90
corresponding to A1[6] structure, the considered structure
should be branched on the C3-linked antenna. The peak
with a GU value of 5.47 contained mainly A2 structure
(Fig. 1c), which had arisen mainly from A2G(4)2 structure
(peak 7; Fig. 1b) by losing two β1-4-linked Gal residues.
This structure did not change its position after treatment
with a mixture of ABS, SPG and BKF enzymes, but upon
additional digestion with JBH enzyme it shifted to the peak
with a GU value of 4.39 corresponding to M3 structure
(Fig. 1e). A broad peak located between the two peaks with
GU values of 5.47 and 6.27 (Fig. 1c) consisted, in fact, of
three small peaks with GU values of 5.73, 5.82 and 5.90,
which contained A1G1, A2B and F(6)A2 structures, respec-
tively. The A2B and F(6)A2 structures had arisen mainly
from A2BG(4)2 (peak 7) and F(6)A2G(4)2 (peak 8; Fig. 1b)
by losing two β1-4-linked Gal residues, respectively. The
A1[6]G1 structure originated from peak 4 (Fig. 1b). The
A2[6]G1 structure was a major component of the peak with
a GU value of 6.27 (Fig. 1c) and resulted from removal of
one β1-4-linked Gal residue from digalactosylated bianten-
nary complex oligosaccharide (peak 7; Fig. 1b). Upon di-
gestion with ABS, SPG, BKF and JBH enzymes (Fig. 1e),
this structure moved and made a substantial contribution to
the peak with a GU value of 5.73. Addition of Jack bean
mannosidase at a concentration of 100 U/ml (JBM; speci-
ficity for α1-2,3,6-linked mannose, Fig. 1f) resulted in the
formation of a peak with a GU value of 4.91. JBM has broad
specificity; although the enzyme will not cleave a single α1-
6-linked mannose residue from core β-mannose, it will
remove a single α1-3-linked mannose from core β-
mannose [25]. In the considered structure, the Gal residue
β1-3-linked to GlcNAc was located on the 6-arm of the core
mannose residue as determined by the product of Jack bean
mannosidase digestion. The peak with a GU value of 7.09
(Fig. 1c) contained mainly the monofucosylated and
monogalactosylated biantennary glycan A2F(3)1G(4)1 that
was present in peak 7 (Fig. 1b) as structure resistant to SPG
treatment. Moreover, this structure had also arisen from the
monofucosylated and digalactosylated biantennary glycan
A2F(3)1G(4)2 (peak 9; Fig. 1b), which upon SPG digestion
lost 0.87 GU, indicating the removal of one galactose. The
presence of α1-3-linked fucose on outer-arm GlcNAc
made it impossible to remove galactose using S. pneu-
moaniae galactosidase. Subsequent digestion with BKF
exoglycosidase (Fig. 1d) did not change this GU value.
Digestion with JBH enzyme caused the loss of one
GlcNAc from the antenna and thereby the formation
of A1F(3)1G(4)1 structure with a GU value of 6.94
(Fig. 1e). Further digestion with JBM showed the arm-
specific location of fucose. One component was digested with
the loss of 1.14 GU, indicating the removal of oneα1-3-linked
mannose residue; the second component was not digested
(Fig. 1f). In a similar manner we identified hybrid, bisected
hybrid, bisected triantennary, tetraantennary and digalactosy-
lated arm α1-3-difucosylated biantennary complex oligosac-
charides as minor constituents of the N-glycan pool.
Normal phase HPLC of L1CAM oligosaccharides
from WM1205Lu metastatic melanoma cells
HPLC data for the 2AB-labelled glycan pool of L1CAM from
metastatic melanoma cells (Fig. 2) were analysed as was done
for the primary analogue. Briefly, HPLC analyses of N-gly-
cans from primary and metastatic L1CAM showed qualitative
and quantitative similarities (Table 1). L1CAM oligosacchar-
ides were heavily sialylated (83.4 % for primary and 75.0 %
for metastatic L1CAM). They were mainly digalactosylated,
biantennary complex-type structures (48.8 % for primary and
41.4 % for metastatic L1CAM). The new monoantennary
structure with a Galβ1-4Galβ1- motif comprised 15.9 % of
primary and 16.4 % of metastatic L1CAM oligosaccharides.
Multiantennary complex-type oligosaccharides were present
at a low level in both glycan pools (5.4 % for primary and 5 %
for metastatic L1CAM). The amount of bisected glycans was
as much as three times higher. There were slightly more
bisected structures in the primary (19.2 %) than in the meta-
static (15.0 %) L1CAMmolecule. One fourth of all structures
possessed Galβ1-3-linked to GlcNAc residue (type 1
LacNAc). Interestingly, for digalactosylated, biantennary
complex-type oligosaccharides the type 1 LacNAc:type 2
LacNAc ratio was reversed to a higher value in the metastatic
glycan pool. This observation is in accord with well-
documented changes in the ratio of type 1:type 2 chains during
carcinogenesis [26]. Furthermore, β1-3-linked Gal residues
were present almost exclusively on the 6-arm in complex-type
glycans, suggesting the presence of site-specific β3-
galactosyltransferase in melanoma. L1CAM from primary
melanoma cells possessed 5.5 % core fucosylated structures
and 5.5 % Lex structures. In metastatic L1CAM the level of
core fucosylated species was lower at 3.6 %, but the amount of
Lex antigen was higher at 6.9 %. Unlike type 2 LacNAc, type
1 LacNAc was not substituted by fucose on the GlcNAc
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Fig. 2 HPLC profiles of the N-
glycan pool of L1CAM from
metastatic WM1205Lu cell line
simultaneously digested with a
series of enzyme arrays. HPLC
analysis of the total glycan pool
a and the products resulting
from the digestion of five
aliquots of the total glycan pool
with a series of enzyme arrays
b–f. See Fig. 1 for legend and
abbreviations
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residue, which prevented the appearance of Lea structures.
Left unidentified were the structures of 10.7 % of primary
and 14.7 % of metastatic L1CAM. They might include
bi- and triantennary polylactosamine complex-type oli-
gosaccharides. The undigested sialylated forms of all
structures found are proposed on the basis of the elution
Table 1 N-linked oligosaccharides in primary and metastatic melanoma L1CAM
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Table 1 (continued)
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positions and the relative areas of the peaks after frac-
tionation of undigested and ABS-treated glycan pools.
The carbohydrate structures deduced from this work are
shown in Table 1.
Table 1 (continued)
PM, data for oligosaccharides of L1CAM from primary melanoma cells; MM, data for oligosaccharides of L1CAM from metastatic melanoma
cells; +, the presence of corresponding structure in L1CAM; −, the absence of corresponding structure in L1CAM
aSymbol representation of glycans as follows: , GlcNAc; , mannose; , galactose; , fucose; , sialic acid; beta linkage, solid line; alpha linkage, dotted
line; 1-4 linkage, horizontal line; 1-3 linkage, (/); 1-2 linkage, vertical line; and 1-6 linkage, (\)
bStructure abbreviations were used as in Fig. 2
cThe corresponding structure is coeluted with a structure of similar GU except structures: M3, A1[6], F(6)A1 and M3, A1[6] in case of L1CAM from primary
and metastatic melanoma cells, respectively
dData for desialylated oligosaccharides
e[M+Na]+
f[M+H]+
gStructure resulted from partial digestion
No determination of the sialic acid linkage can be drawn from NPHPLC and MALDI MS data
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Lectin probes
To confirm the HPLC-identified structures we used a set
of lectins to examine the L1CAM oligosaccharides.
Immunoprecipitation followed by on blot lectin probing
(Fig. 3a) and lectin precipitation followed by on blot
immunodetection of primary and metastatic L1CAM
(Fig. 3b) showed bands of two different weights, 200
and 220 kDa depending on the type of N-glycosylation.
The bands of lower molecular weight showed a positive
reaction with GNA (Fig. 3a). These bands corresponded
to premature forms of L1CAM molecules, as they were
exclusively GNA-positive, meaning that the premature
form of L1CAM possessed only high mannose or high
mannose and hybrid-type oligosaccharides. When lectin
precipitation was used, both lower-molecular bands
showed no GNA-positive reaction (Fig. 3b). It is likely
that the high-mannose chains of the premature forms
were buried within the protein folds and made inacces-
sible to GNA lectin capture. In the case of primary
L1CAM, the band of higher molecular weight was
GNA-positive. The bands of higher molecular weight
also gave positive reactions with other lectins. The
DSA- and LEA-positive bands confirmed the presence
of poly-N-acetyllactosamine species in L1CAM. LEA
binds oligosaccharides containing at least one side
chain, preferentially the C-6 side, with three or more
N-acetyllactosaminyl repeats. On the other hand, DSA
binds oligosaccharides with shorter poly-N-acetyllactosa-
minyl units (two or three N-acetyllactosaminyl repeats)
attached to C-2 and 6 of α-mannose on the C-6 side.
However, LEA and DSA do not bind triantennary oli-
gosaccharides with 2,4-substituted α-mannose and 2-
substituted α-mannose by poly-N-acetyllactosaminyl
units [27]. PHA-L- and PHA-E-positive staining con-
firmed the presence of GlcNAcβ1-6-branched trianten-
nary and/or tetraantennary complex-type glycans and the
presence of bisecting GlcNAc bound to the core man-
nose of complex N-glycans, respectively. A positive
reaction with SNA showed the presence of α2-6-linked
sialic acid. The altered reactivity of primary and meta-
static L1CAM with MAA showed the presence of α2-3-
linked sialic acid only in L1CAM from primary melanoma
(Fig. 3b). For primary L1CAM we did not observe an on blot
MAA-positive reaction after immunoprecipitation (Fig. 3a).
This might be explained by low abundance of α2-3-linked
sialic acid and its relative preferential loss due to sample
boiling before electrophoresis. The presence of fucose and
Fig. 3 Lectin- and Western-blot analysis of L1CAM glycosylation.
Immunoprecipitated L1CAM from primary WM793 and metastatic
WM1205Lu cell lines was probed with a set of lectins a. Immunode-
tection of L1CAM from primary WM793 and metastatic WM1205Lu
cell lines in lectin precipitates, using anti-L1CAM mAb (UJ127.11; 1:
12500) b. Lectin abbreviations and binding specificities are as follows:
GNA, Galanthus nivalis agglutinin (recognises high mannose and
hybrid-type oligosaccharides); DSA, Datura stramonium agglutinin
(recognises two or three N-acetyllactosaminyl repeats); LEA, Lycoper-
sicon esculentum agglutinin (recognises three or more N-
acetyllactosaminyl repeats); PHA-L, Phaseolus vulgaris leucoaggluti-
nin (recognises GlcNAcβ1-6-branched triantennary and tetraantennary
complex-type glycans); PHA-E, Phaseolus vulgaris erythroagglutinin
(recognises bisecting GlcNAc residue); MAA, Maakia amurensis ag-
glutinin (recognises sialic acid α2-3-bound to terminal galactose resi-
due); SNA, Sambucus nigra agglutinin (recognises sialic acid α2-6-
bound to terminal galactose); AAA, Aleuria aurantia agglutinin (rec-
ognises fucose residues); UEA-I, Ulex europaeus I agglutinin (recog-
nises fucose α1-2-bound to terminal galactose residue). CE,
immunodetection of L1CAM in whole cell extract
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monosaccharide residue to which fucose had been bound was
revealed in reactions with AAA and UEA-I lectins. AAA
binds Fucα1-6 linked to the proximal GlcNAc residue as well
as Fucα1-2Galβ1-4GlcNAc sequence (blood group H(0) de-
terminant) and Galβ1-4(Fucα1-3)GlcNAc sequence (Lex de-
terminant). On the other hand, UEA-I recognises only Fucα1-
2 linked to Gal. Both bands of higher molecular weight
showed negative reactions with UEA-I and a positive reaction
with AAA lectin (Fig. 3). These results supported the presence
of core fucose and Lex structure in primary and metastatic
L1CAM. Confocal microscopy yielded the same results
(Fig. 4). The confocal microscope images of cells doubly
labelled, first with a given lectin and then with anti-L1CAM
antibody, showed overlapping of the two stains, observed as
yellow regions, and confirmed the presence of specific glycan
residues in L1CAMmolecules. Overlappingwas not observed
with UEA-I lectin staining, suggesting the absence of Fuc α1-
2-linked to Gal residue. The presence of sialic acid on the cell
surface was revealed using MAA and SNA lectins. In primary
cells, MAA and SNA lectins showed moderate and strong
staining, confirming the presence of α2-3- and α2-6-bound
sialic acid, respectively. Unlike L1CAM from primary cells,
L1CAM from metastatic cells was MAA-negative. Staining
with GNA is not shown because there was no positive reaction
although the staining was repeated three times. As mentioned
before, this discrepancy might be explained by the inaccessi-
bility of high-mannose chains to GNA lectin staining. The
only observed difference in glycosylation patterns between
metastatic L1CAM and L1CAM from primary cells was the
absence ofα2-3-linked sialic acid in the former. We wanted to
find out whether that is a more general hallmark of L1CAM
glycosylation during the transition of melanoma cells from the
vertical growth phase to a metastatic stage. To answer this we
precipitated glycoproteins from four primary and three
metastatic cell lines using MAA and SNA lectins, and
determined that the loss of α2-3-linked sialic acid in
L1CAM is a phenomenon observed during the transition
of melanoma cells from VGP to a metastatic stage
(Supplementary Fig. S2).
Mass spectrometry
We used mass spectrometry to complement the HPLC
analysis of glycans. Since the amount of material available
from each chromatographic peak was not sufficient for mass
spectrometric analysis, we analysed total glycan pools using
MALDI-TOFMS. Beforehand we had enzymatically desialy-
lated both samples to simplify the spectra and thereby achieve
a satisfactory signal-to-noise ratio. Interestingly, even
after prolonged (>24 h) digestion with Sialidase A,
which is known to cleave terminal and branched sialic
acid, Neu5Ac/Neu5Gc desialylation appeared to be
more complete than removal of acetylated Neu5Ac/Neu5Gc.
These data are in agreement with earlier studies on the spec-
ificity of neuraminidases against O-acetylated sialoglycocon-
jugates [28]. It has been shown that human cancers, including
melanoma, can take up and metabolically incorporate the non-
human sialic acid Neu5Gc from dietary sources (or from fetal
bovine serum in the case of cultured human cancer cells).
Moreover, lysates of human melanoma cells had been found
to exhibit O-acetyltransferase activity capable of gener-
ating the O-acetylated sialoglycoconjugates [29]. The
MALDI-MS spectra showed four and six different pseu-
domolecular ions for primary and metastatic glycan pools,
respectively. Among them were two abundant peaks: at m/z
1663.33 [M+Na]+ corresponding to Hex5HexNAc4 composi-
tion, and at m/z 1786.68 [M+H]+ corresponding to
Hex5HexNAc3NeuGc1Ac1 and Hex5HexNAc4dHex1
compositions. The ion at m/z 1908.67 [M+Na]+ corre-
sponded to Hex6HexNAc3NeuGc1 and Hex4HexNAc6
compositions. For the ion at m/z 2038.73 [M+Na/H]+
the following predicted compositions are calculated:
Hex4HexNAc5NeuAc1Ac1, Hex6HexNAc3dHex1NeuAc1,
Hex3HexNAc6dHex2, Hex5HexNAc4NeuAc1Ac2 and
Hex4HexNAc4dHex1NeuGc1Ac2. Two additional ions at
m/z 1296.51 [M+Na]+ corresponding to Hex4HexNAc3 com-
position and at m/z 1501.53 [M+Na]+ corresponding to
Hex4HexNAc4 composition were observed in the sample
from metastatic cells (Supplementary Fig. S3). The
corresponding candidate structures were juxtaposed with the
structures resulting from HPLC analysis (Table 1). Some
oligosaccharides found by HPLC were not confirmed
by MALDI MS. Using ESI-FT-ICR we confirmed the
presence of HexNAc1NeuGc1 and/or Hex1NeuGc1
(3,5AHexNAc and/or
3,5AHex ions at m/z 382.135) and the
presence of Hex2NeuAc1 and/or Hex2NeuGc1 (1,5XCNeuAc
and/or 1,5XCNeuGc ions at m/z 415.107; fragment ions con-
firming the presence of the novel structure) with mass accu-
racy below 2.4 ppm (data not shown).
Functional studies
The wound healing studies were intended to evaluate the
role of cell surface oligosaccharides and L1CAM oligosac-
charides in the migratory behaviour of melanoma cells. The
wounds were allowed to heal in the presence of L1CAM
mAb, SW (a potent inhibitor of complex N-type glycan
processing), MAA, SNA, both L1CAM mAb and SW, or
both L1CAM mAb and lectin. Apparently, primary melano-
ma cells closed the wound faster than metastatic cells did.
The primary cells were much flatter than the metastatic
cells. It was very difficult to see the cell edge with an
inverted microscope (Fig. 5a and b). Basal migration was
normalised to 100 % and the relative closure of wounds was
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calculated (Fig. 5c). In primary cells, mAb alone inhibited
migration more than was seen under treatment with SW
alone, and combined mAb and SW treatment did not result
in further inhibition of primary cell motility. The effects on
primary cell motility were similar for the set of treatments
applying mAb alone, SNA alone and combined SNA and
mAb. It seems that the antibody treatment rather than SWor
SNA treatment influenced the motility of primary cells.
Interestingly, MAA treatment strongly inhibited primary cell
motility, and combined MAA and mAb treatment resulted in
less than additive inhibition, suggesting a significant role for
α2-3-sialylated L1CAM in this process. Immunoinhibition
by L1CAM or SW treatment resulted in stronger inhibition
of cell motility in metastatic cells than in primary cells.
Fig. 4 Confocal microscopy
images of doubly labelled
primary WM793 and metastatic
WM1205Lu cells. Primary a
and metastatic b melanoma
cells were stained with a given
lectin (green) and with anti-
L1CAM antibody (red). Over-
lapping of the two stains (third
and fourth panels), observed as
yellow regions (white arrows),
confirmed the presence of spe-
cific glycan residues in L1CAM
molecules. Nuclei were coun-
terstained with DAPI (blue).
Lectin abbreviations and bind-
ing specificities as in Fig. 4. BF,
bright field
218 Glycoconj J (2013) 30:205–225
These findings suggest a more important role for L1CAM
and the more obvious role of complex-type N-glycans of
metastatic cells in wound healing. Combined SW and mAb
treatment had no additive effect. SNA alone or in concert
with mAb had the same effect as observed in primary cells.
Surprisingly, MAA treatment inhibited metastatic cell
motility by 46 %. Although the surfaces of both types of
cells are α2-3-sialylated (Supplementary Fig. S4), the com-
bined MAA and mAb treatment did not change the level of
inhibition in the case of metastatic melanoma cells. As we
showed above, metastatic L1CAM did not possess α2-3-
linked sialic acid.
Fig. 4 (continued)
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Next we examined whether cell surface oligosaccharides
and L1CAM oligosaccharides could influence the
invasiveness of melanoma cell lines in a matrigel invasion
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WM793 100.0 79.6 91.8 78.9 82.9 82.8 57.4 49.2


























Fig. 5 Effect of cell surface
oligosaccharides and L1CAM
oligosaccharides on repair of
wounds in monolayers of
primary WM793 and metastatic
WM1205Lu melanoma cells.
The cell-coated surface was
scraped with a plastic tip in a
single stripe and covered with
medium supplemented with
10 % FCS. The wounds were
allowed to heal without (con-
trol) or in the presence of anti-
L1CAM antibody (mAb;
10 μg/ml), swainsonine (SW;
10 μl/ml), MAA (50 μg/ml),
SNA (50 μg/ml), both anti-
L1CAM mAb and SW, or both
anti-L1CAM mAb and lectin.
The wounded areas were pho-
tographed immediately after the
cell monolayers scrape-
wounded (0 h) and after 22 h.
The average extent of wound
closure for primary a and
metastatic b cells was quanti-
fied from twenty measurements
of the wound space width in
two separate trials for each
treatment using AxioVision
software (Carl Zeiss). Values
are means ± standard deviation
of three separate experiments
(bars). c Changes in cell mi-
gration rate after antibody, lectin
and SW treatment were calculat-
ed by comparing themigration of
untreated (control; taken as
100 % migration) and treated
cells. Lectin abbreviations and
binding specificities as in Fig. 4.
*P<0.05 and **P<0.01 vs. suit-
able control; ++P<0.01 (Dun-
can’s t test)
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treatment with A. ureafaciens sialidase or S. pneumoniae
sialidase (the latter hydrolyses non-reducing terminal α2-3-
linked sialic acid from complex glycans and glycoproteins),
as well as treatment with both L1CAMmAb and SWor both
L1CAM mAb and sialidase. It should be noted that both cell
lines showed comparable invasiveness (Fig. 6). Antibody
treatment reduced the invasive potential of primary and
metastatic cells by 6 % and 18 % respectively. SW treatment
had no effect on the invasive potential of the primary cell
line and a very low or no effect on the invasiveness of the
metastatic cell line. Treatment with both L1CAM mAb and
SW caused a slight additional reduction of the invasive
potential of the primary cell line and exerted a synergistic
effect in the metastatic cell line (40 % reduction). This
synergistic effect suggests an important role for L1CAM
complex-type glycans in the invasive behaviour of meta-
static cells. ABS treatment strongly inhibited the invasive-
ness of both cell lines (more in metastatic than in primary
cells). In the combined treatment with ABS and L1CAM
mAb, additional inhibition of invasiveness was observed
only in primary cells. The removal of α2-3-linked sialic
acid from the cell surface of primary cells caused 20 %
inhibition of the invasiveness of these cells, and negligible
inhibition in metastatic cells. Combined treatment with S.
pneumoniae sialidase and mAb showed an additional effect,
suggesting the important role of α2-3-linked sialic acid in
the L1CAM molecule in the invasive behaviour of primary
melanoma cells. As demonstrated above, L1CAM of prima-
ry melanoma but not L1CAM of metastatic melanoma pos-
sesses α2-3-linked sialic acid.
Untreated, SW-treated, ABS-treated and S. pneumoniae
sialidase-treated cells were collected, protein cell extracts
were prepared, and the effects of treatment were examined
by western blotting (Supplementary Fig. S5). SW and ABS
treatments shifted the molecular weight of L1CAM to a
lower value in primary and metastatic cells. S. pneumonia
sialidase treatment caused a negligible or no shift of its
molecular weight to a lower value in primary cells. This
can be explained by the low level of α2-3-linked sialic acid
in the primary L1CAM molecule.
Our findings confirm the previous observation that
L1CAM affects migratory behaviour and invasiveness more
strongly in metastatic than in primary melanoma cells [24].
L1CAM from VGP melanoma cells and metastatic cells
showed quite similar glycosylation patterns. This suggests
that oncogenic changes in glycan biosynthesis are estab-
lished in the early stages of melanoma transformation. The
loss of α2-3-linked sialic acid in L1CAM is a phenomenon
observed during the transition of melanoma cells from VGP
to a metastatic stage. The absence of α2-3-sialylated struc-
tures might affect the synthesis of sialyl Lex in L1CAM of
metastatic cells. Possibly the cells from metastatic side no
longer needed the sialylated form of Lex. The presence of
cell surface α2-3-linked sialic acid facilitates the migratory
behaviour and increases the invasiveness of primary mela-
noma cells, and it enhances the motility of metastatic cells.
The presence of cell surface α2-6-linked sialic acid enhan-
ces the invasive potential of both primary (VGP) and meta-
static melanoma cells. Complex-type oligosaccharides in
L1CAM enhance the invasiveness of metastatic melanoma
cells.
Discussion
Our results demonstrate that human melanoma L1CAM
accumulates cancer-associated glycan structures, among
which are β1-6-branched complex-type glycans with or
without N-acetyllactosamine repeats, fucose α1-3-linked to
GlcNAc in the antenna (Lex), low-mannose structures, as
well as GlcNAc-terminated complex-type glycans.
Previously, it was shown that β1-6-branched oligosacchar-
ides are not produced by melanocytes or by cells of early
melanoma in situ but are characteristic structures of florid





WM793 65.9     62.5      65.1     58.9 38.5     36.5      52.5     38.6



































Fig. 6 Effects of L1CAM, complex N-glycans and sialic acid on the
invasiveness of primary WM793 and metastatic WM1205Lu melano-
ma cell lines in a matrigel invasion assay. Fluorescence-labelled cells
were seeded on top of either uncoated or matrigel-coated filters. To
promote invasion the lower part of the chamber was filled with 5 %
FBS. For some experiments, before invasion assays the cells were
grown in the presence of swainsonine (SW; 10 μg/ml) and then the
tumour cells were seeded into the wells either in the presence of SW
(10 μg/ml) or in the presence of SW and anti-L1CAM antibody (mAb;
40 μg/ml). For some experiments, before the invasion assays the cells
were desialylated with neuraminidases from Arthrobacter ureafaciens
(broad specificity) or Streptococcus pneumoniae (removes α2,3 linked
sialic acid) and then tumour cells were incubated in the presence or
absence of anti-L1CAM antibody (40 μg/ml) for another 1 h. Finally,
the tumour cells were seeded into the wells. After 17 h incubation the
fluorescence of cells in lower chambers was measured with a BioTek
Synergy™ instrument. The percentage of cell invasion was calculated
as follows: Formula: % invasion 0 (Mean RFU of cells that invaded
through matrigel-coated membrane/Mean RFU of cells that migrated
through uncoated membrane) * 100. Control was untreated cells. Each
experiment was done twice or three times, with four repetitions for each
sample. Values are means ± standard deviation (bars). **P<0.01 vs.
suitable control; ++P<0.01 vs. suitable mAb-treated cells; # P<0.05
(Duncan’s t test)
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melanoma in situ, as well as invasive and metastatic
tumours [30]. A marked and progressive increase of these
oligosaccharides during the transformation process has been
demonstrated [31]. Melanoma cells with a higher level of
β1-6-branched oligosaccharides displayed a greater abil-
ity to metastasize to lungs and produced larger colonies
[5]. The β1-6-branched N-glycans extended with poly-
N-acetyllactosamine chains facilitate lung-specific metas-
tasis of melanoma cells via galectin-3 [7]. Normal hu-
man melanocytes did not express sLex and poorly
expressed sLea, but melanoma cells from tumour biop-
sies and culture overexpressed both isomers; sLex and
sLea were associated with glycoprotein and glycolipid, re-
spectively [32]. These findings suggested that sLex and sLea
are neoplastic differentiation antigens of melanoma, which are
potentially recognised by selectins and thus may facilitate
tumour progression and metastasis. The metastatic capability
of human melanoma MeWo cells and mouse melanoma B16
cells dramatically increased after acquiring sLex through
transfection of α1,3-fucosyltransferase III (FucT-III) [33,
34]. Recently, the expression of two other cancer-associated
N-glycans was detected in several malignant tumours,
including melanoma and its liver metastases: core fuco-
sylated (Man1-5GlcNAc2Fuc1) and non-fucosylated
(Man1-4GlcNAc2) low-mannose-type and terminal GlcNAc-
structures [35, 36]. Man3GlcNAc2 (Table 1) is expressed on
many glycoproteins of invertebrate organisms, and to a limit-
ed extent on mammalian glycoproteins [35]. Similarly, termi-
nal GlcNAc antigens corresponding to Hex3HexNAc3dHex0-
1 and Hex3HexNAc4 compositions (Table 1) are very rare on
the surface of normal human cells [36]. On the other hand,
malignant human tumours express considerable amounts of
abnormal terminal GlcNAc in protein-linked glycans. These
glycans are specifically accumulated in lung tumour [36].
Curiously, our data unambiguously defined a novel N-glycan
structure containing di- and trisialylated Galβ1-4Galβ1-
4GlcNAc sequence on the 3-arm antenna of monoantennary
complex-type glycan. This result was surprising, because
nothing is presently known about the possible expression of
Galβ1-4Galβ1-4GlcNAc sequence on either glycoproteins or
glycolipids in man or other mammals. The Galβ1-4Galβ1-
4GlcNAc motif monosialylated with either Neu5Gc or
Neu5Ac and/or fucosylated has been identified in eggs of
several fish species [37–39]. A slightly different version with
additional α4-Gal capping instead of sialylation or fucosyla-
tion has also been identified on pigeon serum immunoglobu-
lin G and in O-linked glycans of salivary gland mucin
glycoproteins of the Chinese swiftlet [40, 41]. The uncovered
Galβ1–4Galβ1- motif was found on a glycolipid isolated
from ostrich liver [42]. No clear function has yet been
assigned to Galβ1–4Galβ1- in animal glycoproteins, but it
was demonstrated that Galβ1–4Galβ1- at non-reducing ter-
mini was strongly antigenic, causing “pigeon fancier’s lung”,
a form of extrinsic allergic alveolitis in man [43]. Malignancy
and metastasis are associated with an overall increase in cell-
surface sialic acid content, which in turn reduces the attach-
ment of metastatic tumour cells to matrix components and
thereby promotes and facilitates the migration of benign and
malignant melanocytes. Sialic acids facilitate the association
of malignant cells with selectins, causing interactions of cir-
culating tumour cells with platelets, leukocytes and the endo-
thelium, facilitating metastasis [44]. It is possible that altered
sialylation of tumour cells affects interactions with some
Siglecs found on innate immune cells [44]. An increase in
sialylation is often manifested as a specific increase in α2-6-
linked sialic acid attached to outer N-acetyllactosamine. Apart
from changes in the amount and linkage of sialic acid, there
can also be significant modifications. It has been documented
that sialic acid 9-O-acetylation of gangliosides increased in
melanoma cells. 9-O-acetylneuraminic acid has been recog-
nised as a specific marker for human melanoma cells [29, 45].
Normal human adult melanocytes express a high amount of
Neu5Ac sialic acid, but they do not express acetylated forms
of sialic acids. Since this modification by O-acetylation could
make cells much less susceptible to degradation and extend
their lifetime in vivo, it could be related to the highmalignancy
and rapid spread of human melanoma [46]. Another interest-
ing phenomenon is the aberrant expression of Neu5Gc (HD
antigen) in human cancer cells [47, 48]. More conspicuous
enrichment of Neu5Gc in carcinomas could be caused by
higher uptake by these rapidly growing tissues [49]. Here we
have shown that L1CAM protein can also carry an acetylated
form of sialic acid in human melanoma. To our knowledge,
A1[3]G(4)2 structure [Galβ1-4Galβ1-4GlcNAcβ1-2Manα1-
3(Manα1-6)Manβ1-4GlcNAcβ1GlcNAc] of L1CAM acet-
ylated on sialic acid is the first cancer biomarker related to
metabolic replacement of Neu5Ac with the immunogenic
dietary NeuGc molecule in protein-linked N-glycans. The
coexistence of acetylated N-glycolylneuraminic acid with
Galβ1-4Galβ1-4GlcNAc sequence in A1[3]G(4)2 structure
generated a novel, unique neo-tumour-associated xeno-
autoantigen in human melanoma. The appearance (or elevated
amounts as compared with healthy cells) of any one of the
above mentioned cancer-related oligosaccharide sequences on
the cell surface indicates the cancerous nature of the cells or
tissues. This report is the first to describe simultaneous ex-
pression of all the above-mentioned cancer-related antigens in
L1CAM from human melanoma.
Tumour-specific expression and antibody recognition of
the above-mentioned carbohydrate epitopes have been de-
scribed for human IgM antibodies. IgM titers to sLex anti-
gen are low in sera of normal individuals and high in sera of
melanoma patients [32]. Normally, there are large amounts
of antibodies recognizing terminal GlcNAc structures in
human serum [50]. High titer of a natural antibody against
terminal Galβ1–4Galβ1- was detected in human sera; the
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anti-Galβ1–4Galβ1- antibodies were mainly IgM and oc-
curred in a large population [42]. Humans have varying and
sometimes substantial levels of circulating antibodies direct-
ed against Neu5Gc antigen [51]. This antigen is known to
trigger a potent immune reaction. In a human-like Neu5Gc-
deficient mouse model, tumour-associated Neu5Gc inter-
acted with low levels of circulating anti-Neu5Gc antibodies,
thereby facilitating tumour progression via chronic inflam-
mation and angiogenesis [52]. Thus, a weak immune re-
sponse is considered to be favourable to tumour growth.
Perhaps this is why the Galβ1–4Galβ1-4GlcNAc antigen
presented in our study, an antigen potent enough to trigger a
strong immune reaction, is masked by sialic acid. The acet-
ylated form of sialic acid, more resistant to neuraminidase
treatment, protects cells carrying these residues from apopto-
sis. Since cancer cells shed the L1CAM ectodomain into
circulation, the NeuGcAcGalβ1-4Galβ1-4 xeno-autoantigen
potentially gives us a novel serum biomarker for early detec-
tion of melanoma. This new structure presents an opportunity
to identify other novel glycosyltransferase activities such as
the galactosyltransferase activity involved in synthesis of the
Galβ1-4Galβ1-4GlcNAc sequence. We are aware of the lim-
itation of in vitro model, which bases on cells maintained in
medium supplemented with foetal bovine serum– a source of
NeuGc. Interpretation of cancer uptake of nonhuman NeuGc
by melanoma cells must be integrated with clinical and histo-
pathological studies to avoid misleading judgement.
Conclusions
Here we showed for the first time that (i) the sialic acid linkage
position in L1CAM could effectively discriminate between the
VGP primary and the metastatic stage of human melanoma,
and (ii) A1[3]G(4)2S2-3 oligosaccharide is a new melanoma-
associated carbohydrate antigen, absent from the normal cell
surface and resulting from alteration of N-glycan biosynthesis.
Further work should more precisely determine the glycosyla-
tion pattern of L1CAM in different stages of melanoma pro-
gression, especially the diversity in sialic acid content. Also,
the biological significance of Galβ1–4Galβ1- in human mel-
anoma remains to be established. Whether Galβ1–4Galβ1- is
located specifically on L1CAM glycoprotein or on glycopro-
teins of other tumours and cancer is another question to answer.
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